

Review Assessment

Anakinra, human recombinant interleukin-1 receptor
antagonist (Kineret™) (No. 05/02)
Amgen

Summary of Recommendation

8 November, 2002

The Scottish Medicines Consortium (SMC) has completed its review assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

ADVICE

On the basis of the currently available evidence Anakinra is not recommended for use in NHS Scotland

REASONS FOR ADVICE

The company have produced no additional data to indicate a susceptible target population for this biological product which does not appear to be as effective as competitor products, and is not particularly cost effective.

Professor David H Lawson
Chairman